Danielle T. Vlazny

Danielle T. Vlazny

Auto-generated profile, based on publicly available information

Danielle T. Vlazny

Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
WWWaldemar E. Wysokinski
Waldemar E. Wysokinski
DFDavid A. Froehling
David A. Froehling
DHDamon E. Houghton
Damon E. Houghton
RMRobert D. McBane
Robert D. McBane
DVDanielle T. Vlazny
Danielle T. Vlazny
ACAna Casanegra
Ana Casanegra

7 April 2021 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
NBNichole Brunton
Nichole Brunton
WWWaldemar E. Wysokinski
Waldemar E. Wysokinski
DHDavid O. Hodge
David O. Hodge
DVDanielle T. Vlazny
Danielle T. Vlazny
DHDamon E. Houghton
Damon E. Houghton
ACAna Casanegra
Ana Casanegra
Objective We assessed the number of cases with delayed anticoagulation initiation, explored the reasons for the delay, and its impact on outcome in patients with acute venous thromboembolism (VTE) treated in an organized setting of treatment initiation and continuous, prospective follow‐up. Methods Patients with anticoagulation initiation delay >24 hours were identified within the cohort of patients with acute VTE enrolled in the Mayo Clinic Venous Thromboembolism Registry between 2013 and 2020. The reasons for treatment delay were explored by reviewing the electronic database. VTE recurrence, all‐cause mortality, major bleeding, and clinically relevant nonmajor bleeding (CRNMB) were compared to those with no anticoagulation delay. Results Of 2378 patients with acute VTE, 100 (4.2%) experienced an anticoagulation delay. We identified seven reasons for treatment delays: deferring anticoagulation initiation to specialists (n = 38), thrombocytopenia (n = 10), planned or recent procedure (n = 16), active or recent bleeding (n = 12), missed diagnosis (n = 7), logistics (n = 6), and patient decision (n = 4). In seven cases, no reason was identified. We identified modifiable reasons for anticoagulation delay in 55%. At 90‐day follow‐up, patients with anticoagulation delay had a higher rate of mortality and major bleeding. VTE recurrence and CRNMB were not statistically different compared to those without anticoagulation delay. After adjustment for age, weight, and cancer, hazard ratios (HRs) for VTE recurrence and major bleeding remained elevated but not to a statistically significant level. Conclusion In the setting of a highly organized system of anticoagulation initiation, the incidence of treatment delay is low. Yet most delays could be avoided. A low number of cases provide insufficient power to evaluate the clinical consequences of anticoagulation initiation delay; however, elevated HR for VTE recurrence and major bleeding suggest association and need for further investigation.

29 April 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
DVDanielle T. Vlazny
Danielle T. Vlazny
RMRobert D. McBane
Robert D. McBane
ACAna Casanegra
Ana Casanegra
DHDavid O. Hodge
David O. Hodge
TLTeresa Lang
Teresa Lang
DHDamon E. Houghton
Damon E. Houghton
Low-dose direct oral anticoagulants (DOACs) have been studied in randomized controlled trials for extended prevention of venous thromboembolism (VTE) after 6 months at therapeutic doses. This study examined the effectiveness, safety, and utilization of low-dose DOACs in a real-world cohort with dedicated analysis of cancer patients. Consecutive patients enrolled in the Mayo Clinic VTE Registry from March 1, 2013, to December 31, 2022, were followed prospectively for VTE recurrence, major bleeding (MB), and clinically relevant non-MB (CRNMB). Patients with events during the first 3 months were excluded. After anticoagulation for 3 months with either rivaroxaban or apixaban, characteristics and outcomes of patients continuing anticoagulation were evaluated by Cox regression and a nested case-control study. In total, 466 patients (71% apixaban and 29% rivaroxaban) were identified on low-dose DOACs and 2273 in the full-dose group. Demographics between groups were mostly similar. Patients with active cancer as a provoking factor were less common in the overall low-dose DOAC group. In Cox regression analysis, VTE recurrence was not different between any groups. In noncancer patients, CRNMB but not MB was decreased in the low-dose group (hazard ratio [HR], 4.97; P < .001). In patients with cancer, low-dose DOACs were protective for MB (HR, 4.48; P = .001) and CRNMB (HR, 6.81; P < .001). Bleeding outcomes were the same in nested case-control analysis as well. Dose reduction maintains low recurrence rates but also decreases bleeding, with the most pronounced effect in the cancer population.


20 March 2024 in Vascular Medicine
Verified
Journal Article
Open access
ABAlexandra Moran Baird
Alexandra Moran Baird
KHKatherine Hays
Katherine Hays
DVDanielle Vlazny
Danielle Vlazny

10 June 2026 in Vascular Medicine
Verified
Journal Article
Closed access
SASyed Ahsan
Syed Ahsan
KCKevin Cohoon
Kevin Cohoon
CECarlos Echevarria
Carlos Echevarria
SHStanislav Henkin
Stanislav Henkin
SSSahibaan Sondh
Sahibaan Sondh
AYAditi Yadav-Malhorta
Aditi Yadav-Malhorta